BioNTech SE Chief Executive Officer Ugur Sahin filed a Form 4 with the SEC on September 18, 2026, disclosing the sale of 64,000 ordinary shares across two transactions on September 17 and September 18, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Two-day sale: Sahin disposed of 34,000 ordinary shares on September 17, 2026, at $98.5983 per share, and 30,000 ordinary shares on September 18, 2026, at $96.2243 per share.
  • Direct ownership after sales: Following the transactions, Sahin directly held 489,209 ordinary shares.
  • Large indirect stake: Sahin also indirectly beneficially owns 39,218,111 ordinary shares held by Medine GmbH, of which he is the sole shareholder.
  • Trust arrangement: According to the filing, 106,721 of the shares held by Medine GmbH are held for the benefit of an individual under a trust arrangement, over which Medine GmbH exercises voting power but not dispositive power.
  • 10b5-1 plan: The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
  • Roles: Sahin is identified in the filing as Chief Executive Officer, Director, and a 10% owner of BioNTech SE (NASDAQ:BNTX).

Sahin's Share Sales and Beneficial Ownership Structure at BioNTech

According to the Form 4 filed with the SEC, Ugur Sahin, Chief Executive Officer of BioNTech SE, sold a combined 64,000 ordinary shares over two consecutive trading days. On September 17, 2026, he disposed of 34,000 shares at a price of $98.5983 each. The following day, September 18, 2026, he sold an additional 30,000 shares at $96.2243 each. Both transactions are coded "S" (sale) and are listed as direct dispositions. After these two sales, Sahin's directly held position stood at 489,209 ordinary shares, the filing disclosed.

The filing also details a substantial indirect ownership position. Sahin is reported to beneficially own 39,218,111 ordinary shares indirectly through Medine GmbH, a company of which he is the sole shareholder. The filing notes that 106,721 of those shares are held for the benefit of an individual under a trust arrangement, under which Medine GmbH holds voting power but not dispositive power over those particular shares for as long as they remain in trust.

The filing specifies that both sales were carried out under a Rule 10b5-1 trading plan that Sahin established on June 3, 2026. The Form 4 was signed by Humza Bokhari as Attorney-in-Fact and dated September 18, 2026. The filing notes the box was checked indicating the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

The Form 4 disclosed two open-market sales of BioNTech ordinary shares by CEO Ugur Sahin totaling 64,000 shares on September 17 and 18, 2026, under a pre-established 10b5-1 plan, along with details of his direct and indirect beneficial ownership positions.